Top

Published in:

01-02-2012 | Review Article

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review

Authors: Christos G. Mihos, Rosa T. Artola, Orlando Santana

Published in: Rheumatology International | Issue 2/2012

Abstract

The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment for hyperlipidemia. They have also demonstrated a benefit in a variety of other disease processes, including a wide range of rheumatologic disorders. These secondary actions are known as pleiotropic effects. Our paper serves as a focused and updated discussion on the pleiotropic effects of statins in rheumatologic disorders and emphasizes the importance of randomized, placebo-controlled trials to further elucidate this interesting phenomenon.

Pignone M, Phillips C, Mulrow C (2000) Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ. 321:983–985PubMedCrossRef

Tonkin A, Aylward P, Colquhoun D et al. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. N Engl J Med 339(19):1349–1357

Endres M (2005) Statins and stroke. J Cereb Blood Flow Metab 25(9):1093–1110PubMedCrossRef

Liao JK (2002) Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 86(1):5–18PubMedCrossRef

Li J, Li JJ, He JG, Nan JL, Guo YL, Xiong CM (2010) Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappa B pathway. Cardiovasc Ther 28(1):8–14PubMedCrossRef

Tandon V, Bano G, Khajuria V, Parihar A, Gupta S (2005) Pleiotropic effects of statins. Indian J Pharmacol 37(2):77–85CrossRef

Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Müller GA (2009) Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 38(4):235–239PubMedCrossRef

Lazzerini PE, Lorenzini S, Selvi E et al. (2007) Simvastatin inhibits cytokine production and nuclear factor-k B activation in interleukin 1-beta stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol 25(5):696–700

Xu H, Liu P, Liang L et al (2006) RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 54(11):3441–3451PubMedCrossRef

10.

Connor AM, Berger S, Narendran A, Keystone EC (2006) Inhibition of protein geranylgeranylation induces apoptosis in synovial fibroblasts. Arthritis Res Ther 8(4):R94PubMedCrossRef

11.

Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S (2006) Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54(2):579–586PubMedCrossRef

12.

Yokota K, Miyoshi F, Miyazaki T et al (2008) High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 35(2):193–200PubMed

13.

Tikiz C, Utuk O, Pirildar T et al (2005) Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long-term rheumatoid arthritis. J Rheumatol 32(11):2095–2101PubMed

14.

Haruna Y, Morita Y, Yada T, Satoh M, Fox DA, Kashihara N (2007) Fluvastatin reverses endothelial dysfunction and increased vascular oxidative stress in rat adjuvant-induced arthritis. Arthritis Rheum 56(6):1827–1835PubMedCrossRef

15.

Kinderlerer AR, Steinberg R, Johns M et al (2006) Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res Ther 8(4):R130PubMedCrossRef

16.

Paumelle R, Blanquart C, Briand O et al (2006) Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 98(3):361–369PubMedCrossRef

17.

Lin H, Xiao Y, Chen G et al. (2010) HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. Rheumatol Int. 15 May 2010. (in press)

18.

Weitz-Schmidt G, Welzenbach K, Brinkmann V et al (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7(6):687–692PubMedCrossRef

19.

McCarey DW, McInnes IB, Madhok R et al (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 363(9426):2015–2021PubMedCrossRef

20.

Shirinsky IV, Zheltova OI, Solovyova NY, Kozlov VA (2009) Shirinsky versus changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 38(1):23–27PubMedCrossRef

21.

Mäki-Petäjä KM, Booth AD, Hall FC et al (2007) Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 50(9):852–858PubMedCrossRef

22.

Okamoto H, Koizumi K, Kamitsuji S et al (2007) Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 34(5):964–968PubMed

23.

Bansback N, Ara R, Ward S, Anis A, Choi HK (2009) Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. Pharmacoeconomics 27(1):25–37PubMedCrossRef

24.

Chodick G, Amital H, Shalem Y et al (2010) Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 7(9):e1000336PubMedCrossRef

25.

Jick SS, Choi H, Li L, McInnes IB, Sattar N (2009) Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 68(4):546–551PubMedCrossRef

26.

Orozco P (2004) Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol 19(12):1105–1112PubMedCrossRef

27.

Hanayama R, Shimizu H, Nakagami H et al (2009) Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. Int J Mol Med 23(5):581–588PubMed

28.

Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB (2008) Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 123(8):1733–1740PubMedCrossRef

29.

Staal A, Frith JC, French MH et al (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18(1):88–96PubMedCrossRef

30.

Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW, Lin FH (2010) Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Res 30(3):191–199PubMedCrossRef

31.

Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N (2004) Induction of osteoblast differentiation indices by statins in MC3T3–E1 cells. J Cell Biochem 92(3):458–471PubMedCrossRef

32.

Li X, Cui Q, Kao C, Wang GJ, Balian G (2003) Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33(4):652–659

33.

Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW (2001) Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab 86(9):4556–4559PubMedCrossRef

34.

Uyar Y, Baytur Y, Inceboz U, Demir BC, Gumuser G, Ozbilgin K (2009) Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats. Maturitas 63(3):261–267PubMedCrossRef

35.

Du Z, Chen J, Yan F, Xiao Y (2009) Effects of simvastatin on bone healing around titanium implants in osteoporotic rats. Clin Oral Implants Res 20(2):145–150PubMedCrossRef

36.

Wang JW, Xu SW, Yang DS, Lv RK (2007) Locally applied simvastatin promotes fracture healing in ovariectomized rat. Osteoporos Int 18(12):1641–1650PubMedCrossRef

37.

Hatzigeorgiou C, Jackson JL (2005) Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis. Osteoporos Int 16(8):990–998PubMedCrossRef

38.

Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2007) Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40(6):1581–1587PubMedCrossRef

39.

Yue J, Zhang X, Dong B, Yang M (2010) Statins and bone health in postmenopausal women: a systematic review of randomized controlled trials. Menopause 17(5):1071–1079PubMedCrossRef

40.

Bauer DC, Mundy GR, Jamal SA et al (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164(2):146–152PubMedCrossRef

41.

Pérez-Castrillón JL, Vega G, Abad L et al (2008) Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome. Ann Nutr Metab 53(2):117–121PubMedCrossRef

42.

Pérez-Castrillón JL, Vega G, Abad L et al. (2009) Atorvastatin and BMD in coronary syndrome. Role of Lys656Asn polymorphism of leptin receptor gene. Endocr J 56(2):221–225

43.

Bakhireva LN, Shainline MR, Carter S et al (2010) Synergistic effect of statins and postmenopausal hormone therapy in the prevention of skeletal fractures in elderly women. Pharmacotherapy 30(9):879–887PubMedCrossRef

44.

Tanriverdi HA, Barut A, Sarikaya S (2005) Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur J Obstet Gynecol Reprod Biol 120(1):63–68PubMedCrossRef

45.

De Leo V, Morgante G, la Marca A, Lanzetta D, Cobellis L, Petraglia F (2003) Combination of statins and hormone replacement therapy in postmenopausal women is associated with increased bone mineral density. Gynecol Endocrinol 17(4):329–332PubMed

46.

Amuro H, Ito T, Miyamoto R et al (2010) Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 62(7):2073–2085PubMed

47.

Ferreira GA, Teixeira AL, Sato EI (2010) Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus 19(8):927–934PubMedCrossRef

48.

Jury EC, Isenberg DA, Mauri C, Ehrenstein MR (2006) Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol 177(10):7416–7422PubMed

49.

Shimazu H, Kinoshita K, Hino S et al (2010) Effect of combining ACE inhibitor and statin in lupus-prone mice. Clin Immunol 136(2):188–196PubMedCrossRef

50.

Woo JM, Lin Z, Navab M et al (2010) Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther 12(3):R93PubMedCrossRef

51.

Aprahamian T, Bonegio R, Rizzo J et al (2006) Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 177(5):3028–3034PubMed

52.

Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR (2004) Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice. J Immunol 173(12):7641–7646PubMed

53.

Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS (2010) Lupus atherosclerosis prevention study (LAPS). Ann Rheum Dis 70(5):760–765

54.

Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI (2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford) 46(10):1560–1565CrossRef

55.

Belmont HM, Lydon E (2005) Avascular necrosis prevention with lipitor in lupus erythematosus. Lupus 14(10):869–870PubMedCrossRef

56.

Del Papa N, Cortiana M, Vitali C et al (2008) Simvastatin reduces endothelial activation and damage but is partially ineffective in inducing endothelial repair in systemic sclerosis. J Rheumatol 35(7):1323–1328PubMed

57.

Abou-Raya A, Abou-Raya S, Helmii M (2007) Statins as immunomodulators in systemic sclerosis. Ann NY Acad Sci. 1110:670–680PubMedCrossRef

58.

Kuwana M (2006) Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol 18(6):594–600PubMedCrossRef

59.

Louneva N, Huaman G, Fertala J, Jiménez SA (2006) Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 54(4):1298–1308PubMedCrossRef

60.

Abou-Raya A, Abou-Raya S, Helmii M (2008) Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol 35(9):1801–1808PubMed

61.

Kuwana M, Okazaki Y, Kaburaki J (2009) Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod Rheumatol 19(5):530–535PubMedCrossRef

62.

Simopoulou T, Malizos KN, Poultsides L, Tsezou A (2010) Protective effect of atorvastatin in cultured osteoarthritic chondrocytes. J Orthop Res 28(1):110–115PubMed

63.

Sverdrup FM, Yates MP, Vickery LE et al (2010) Protein geranylgeranylation controls collagenase expression in osteoarthritic cartilage. Osteoarthritis Cartilage 18(7):948–955PubMedCrossRef

64.

Litinsky I, Golan I, Yaron M, Yaron I, Caspi D, Elkayam O (2009) Simvastatin induces apoptosis of fibroblast-like synoviocytes. Open Rheumatol J. 3:35–40PubMedCrossRef

65.

Lazzerini PE, Capecchi PL, Nerucci F et al (2004) Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann Rheum Dis 63(7):867–869PubMedCrossRef

66.

Rabinowitz JL, Gregg JR, Nixon JE, Schumacher HR (1979) Lipid composition of the tissues of the human knee joints. I—Observations in normal joints (articular cartilage, meniscus, ligaments, synovial fluid, synovium, intra-articular fat pad and bone marrow). Clin Orthop Relat Res (143):260–265

67.

Pritchett JW (2007) Statins and dietary fish oils improve lipid composition in bone marrow and joints. Clin Orthop Relat Res. 456:233–237PubMed

68.

Akasaki Y, Matsuda S, Nakayama K, Fukagawa S, Miura H, Iwamoto Y (2009) Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 17(2):235–243PubMedCrossRef

69.

Akasaki Y, Matsuda S, Iwamoto Y (2009) Progress of research in osteoarthritis. The anti-inflammatory effects of intra-articular injected statin on experimental osteoarthritis. Clin Calcium 19(11):1653–1662

70.

López-Pedrera C, Ruiz-Limón P, Aguirre MA et al. (2010) Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 70(4):675–682

71.

Jajoria P, Murthy V, Papalardo E, Romay-Penabad Z, Gleason C, Pierangeli SS (2009) Statins for the treatment of antiphospholipid syndrome? Ann N Y Acad Sci 1173:736–745PubMedCrossRef

72.

Meroni PL, Raschi E, Testoni C et al (2001) Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 44(12):2870–2878PubMedCrossRef

73.

Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G (2008) Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 118(10):3453–3461PubMed

74.

Ferrara DE, Liu X, Espinola RG et al (2003) Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 48(11):3272–3279PubMedCrossRef

75.

Vasiuk IuA, Perlamutrov IuN, Shkol’nik MN, Shkol’nik EL (2010) Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension. Kardiologiia. 50(3):37–46

76.

Naseri M, Hadipour A, Sepaskhah M, Namazi MR (2010) The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger J Med 19(1):58–61PubMed

77.

Hamaoka A, Hamaoka K, Yahata T et al (2010) Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease. J Cardiol 56(2):245–253PubMedCrossRef

78.

Huang SM, Weng KP, Chang JS et al (2008) Effects of statin therapy in children complicated with coronary arterial abnormality late after kawasaki disease: a pilot study. Circ J 72(10):1583–1587PubMedCrossRef

79.

van Denderen JC, Peters MJ, van Halm VP et al (2006) Statin therapy might be beneficial for patients with ankylosing spondylitis. Ann Rheum Dis 65(5):695–696PubMedCrossRef

80.

Inanc MT, Kalay N, Heyit T et al (2010) Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Behçet’s disease. Echocardiography 27(8):997–1003PubMedCrossRef

81.

Hashimoto T, Toya Y, Kihara M et al (2008) Behçet’s disease complicated by IgA nephropathy with nephrotic syndrome. Clin Exp Nephrol 12(3):224–227PubMedCrossRef

82.

ten Cate R, Nibbering PH, Bredius RG (2004) Therapy-refractory systemic juvenile idiopathic arthritis successfully treated with statins. Rheumatology (Oxford) 43(7):934–935CrossRef

83.

Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116(6):408–416PubMedCrossRef

84.

Sailler L, Pereira C, Bagheri A et al (2008) Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis 67(5):614–619PubMedCrossRef

85.

Sen D, Rosenstein ED, Kramer N (2010) ANCA-positive vasculitis associated with simvastatin/ezetimibe: expanding the spectrum of statin-induced autoimmunity? Int J Rheum Dis 13(3):e29–e31PubMedCrossRef

86.

Haroon M, Devlin J (2008) A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol 27(Suppl 2):S75–S77PubMedCrossRef

87.

Noel B (2007) Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21(1):17–24PubMedCrossRef

88.

Goëb V, Guillemant N, Vittecoq O, Le Loët X (2004) Cerivastatin-induced polymyalgia rheumatica-like illness. Clin Rheumatol 23(2):179PubMedCrossRef

89.

Yamamoto M, Ikeda M, Kodama H, Sano S (2008) Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol 35(11):732–736PubMedCrossRef

90.

Adams AE, Bobrove AM, Gilliam AC (2010) Statins and “chameleon-like” cutaneous eruptions: simvastatin-induced acral cutaneous vesiculobullous and pustular eruption in a 70-year-old man. J Cutan Med Surg 14(5):207–211PubMed

91.

Adams AE, Bobrove AM, Gilliam AC (2010) Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry. Ann Rheum Dis 70(5):877–878

92.

Aronow C, Diamond B. A double blind, placebo controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. National Institute of Allergy and Infectious Diseases. Clinialtrials gov NCT00302952

93.

Ming Li EK. Effects of HMG-coA reductase inhibitor on progression of carotid intima-media thickness and arterial stiffness in rheumatoid arthritis. The Chinese University of Hong Kong. Clinicaltrial gov NCT00555230

94.

Ansell BJ. Effects of atorvastatin on disease activity and HDL cholesterol anti-inflammatory properties in patients with rheumatoid arthritis. The University of California, Los Angeles. Clinicatrial gov NCT00356473

95.

Pfizer, Inc. Phase 2 study of the effects of open-label CP-690,550 and double-blind atorvastatin on lipids in patients with active rheumatoid arthritis. Clinicaltrial gov NCT01059864

96.

Abdou NI. Statins and Lupus: effects of statins on clinical lupus parameters, serological markers and toll-like receptors. St. Luke’s Hospital. Clinicaltrial gov NCT00519363

97.

Lai NS. An open labeled pilot study of atorvastatin in systemic lupus erythematosus. Buddhist Dalin Chi Tzu General Hospital. Clinicaltrial gov NCT00432354

98.

Schanberg LE. A multicenter, randomized, double-blind, placebo-controlled study to test the safety and efficacy of lipitor (atorvastatin) in reducing the progression of carotid IMT in early childhood SLE. Duke University. Clinicaltrial gov NCT00065806

99.

Belmont HM. Atorvastatin to prevent avascular necrosis of bone in steroid treated exacerbated systemic lupus erythematosus. New York University. Clinicaltrial gov NCT00412841

100.

Erkan D, Pierangeli S. Effects of fluvastatin on proinflammatory and prothrombotic markers in antiphospholipid syndrome patients. Hospital for Special Surgery. Clinicaltrial gov NCT00674297

Title: The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review
Authors: Christos G. Mihos
Rosa T. Artola
Orlando Santana
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 2/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-011-2008-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus

Investigation of the veins in patients with Behçet’s disease with no known vascular event by Doppler ultrasonography

Insulin-like growth factor I receptor density on CD4+T-lymphocytes from active early steroid- and DMARD-naïve rheumatoid arthritis patients is up-regulated and not influenced by 1 year of clinically effective treatment

Polyarteritis nodosa and Henoch–Schönlein purpura nephritis in a child with familial Mediterranean fever: a case report

Systemic-onset juvenile idiopathic arthritis complicated by early onset amyloidosis in a patient carrying a mutation in the MEFV gene

Serum levels of soluble CD21 in patients with systemic sclerosis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials